SCHEMBL14969436

SCHEMBL14969436

Cc1cc(C)c(CNC(=O)c2ccc(CCCOc3ccccc3C)cc2)c(O)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.44
KMT2A Q03164 4/20 0.42
RXRA P19793 1/20 0.41
RXRB P28702 1/20 0.41
RXRG P48443 1/20 0.41
MEN1 O00255 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
MAPT P10636 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
CNR2 P34972 1/20 0.38
TRPV1 Q8NER1 1/20 0.38
KDM4E B2RXH2 1/20 0.38
PKM P14618 1/20 0.38
KLKB1 P03952 1/20 0.38
PPARG P37231 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14966474 0.95 MAPK14 (0.44) MAPK14KMT2ARXRARXRBRXRG
SCHEMBL14966965 0.89 NPC1 (0.47) MAPK14KMT2AMEN1SMN1; SMN2MAPT
SCHEMBL14966879 0.88 MAPK14 (0.39) MAPK14KMT2AMEN1SMN1; SMN2MAPT
SCHEMBL14966935 0.87 RAB9A (0.46) MAPK14KMT2ANPC1RAB9AL3MBTL1
SCHEMBL14966781 0.84 RAB9A (0.47) SMN1; SMN2MAPTNPC1RAB9AALDH1A1
SCHEMBL14966659 0.84 LMNA (0.48) MAPK14KMT2AMEN1SMN1; SMN2MAPT
SCHEMBL14967254 0.84 MAPK14 (0.42) MAPK14KMT2AMEN1SMN1; SMN2MAPT
SCHEMBL14966830 0.83 KLKB1 (0.44) KMT2AMEN1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL14966459 0.82 KLKB1 (0.40) KMT2AMEN1SMN1; SMN2TRPV1KDM4E
SCHEMBL14966576 0.82 KLKB1 (0.43) KMT2ASMN1; SMN2L3MBTL1ALDH1A1KLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206128-B2 Modulators of methyl modifying enzymes, compositions and uses thereof CONSTELLATION PHARMACEUTICALS, INC. (US) 2015-12-08 US disclosed
US-20140288123-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. 2014-09-25 US disclosed
EP-2780014-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF Constellation Pharmaceuticals, Inc. (US) 2014-09-24 EP disclosed
WO-2013075083-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS (US) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288123-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF TET1, TET3, EHMT2 MAPK14 4092/4885KMT2A 84/4885RXRA 1639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.